- Home
- INVA vs GYRE Comparison
INVA vs GYRE Comparison
Compare INVA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- GYRE
- Stock Information
- Founded
- INVA 1996
- GYRE 2002
- Country
- INVA United States
- GYRE United States
- Employees
- INVA N/A
- GYRE N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- GYRE Health Care
- Exchange
- INVA Nasdaq
- GYRE Nasdaq
- Market Cap
- INVA 1.2B
- GYRE 1.3B
- IPO Year
- INVA 2004
- GYRE N/A
- Fundamental
- Price
- INVA $17.55
- GYRE $12.45
- Analyst Decision
- INVA Buy
- GYRE
- Analyst Count
- INVA 1
- GYRE 0
- Target Price
- INVA N/A
- GYRE N/A
- AVG Volume (30 Days)
- INVA 643.1K
- GYRE 150.7K
- Earning Date
- INVA 11-06-2024
- GYRE 11-13-2024
- Dividend Yield
- INVA N/A
- GYRE N/A
- EPS Growth
- INVA 46.55
- GYRE N/A
- EPS
- INVA 0.99
- GYRE N/A
- Revenue
- INVA $352,745,000.00
- GYRE $105,033,000.00
- Revenue This Year
- INVA $16.20
- GYRE $25.32
- Revenue Next Year
- INVA N/A
- GYRE $12.95
- P/E Ratio
- INVA $17.72
- GYRE N/A
- Revenue Growth
- INVA 21.46
- GYRE N/A
- 52 Week Low
- INVA $14.33
- GYRE $8.26
- 52 Week High
- INVA $21.28
- GYRE $27.45
- Technical
- Relative Strength Index (RSI)
- INVA 20.61
- GYRE 54.54
- Support Level
- INVA $17.85
- GYRE $10.39
- Resistance Level
- INVA $18.69
- GYRE $12.59
- Average True Range (ATR)
- INVA 0.34
- GYRE 1.16
- MACD
- INVA -0.08
- GYRE 0.37
- Stochastic Oscillator
- INVA 6.74
- GYRE 59.01
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.